Folate Alpha Targeting: Exciting New Options for Platinum Resistance Ovarian Cancer Patients

Description

Recorded Live: July 21, 2022

Speaker & Presentation Information

Moderator:
Rob Coleman, MD

Panelists:
David O'Malley, MD
Kathleen Moore, MD, MS

Supported in part by

Summary

Availability:

On-Demand

Cost:

FREE

Create Account

Recommended

Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study Results

FREE

Treatment Options for Platinum Resistant Ovarian Cancer

FREE

An Evolving Frontier: Endometrial Cancer Treatment

FREE

Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

FREE

International Gynecologic Cancer Society and International Journal of Gynecological Cancer Evidence-Based Medicine for Gynecological Oncology Curriculum (EBM on the GO)

FREE

Redefining Platinum Sensitivity : Additional Treatment Considerations in a Changing Paradigm

FREE

Journal Club:Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE)

FREE

IGCS 2024 Endometrial Cancer Master Session

FREE

Uterine Cancers in the Molecular Era: Changing Trends and Implications

FREE

Journal Club: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

FREE